EC pledges €4.9bn to grant access to medicinesUnder the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries. more ➔
BioGeneration Ventures closes BGV IV Fund at €105mBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m. more ➔
LSP leads €11m Series A round in OneProjectOneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP. more ➔
Illumina and Epidarex Capital invest in post-Brexit UKIllumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs. more ➔
Novel adjuvant teases T cells to respond to HCV Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response. more ➔
First drug found to reduce COVID-19-mortalityA clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients. more ➔
Germany puts €300m in CureVac AG for COVID-19 vaccineIn the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG. more ➔
Abbvie and Genmab team up in oncologyAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats. more ➔
Evox Therapeutics signs US$1.2bn deal with Eli LillyEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases. more ➔
Calliditas Therapeutics raise US$90m in Nasdaq IPOSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO. more ➔
